Ischemic StrokePRACTISENCT05355831
Patient-tailored Transcranial Direct Current Stimulation to Improve Stroke Rehabilitation
A study testing Active Transcranial Direct Current Stimulation in people with Ischemic Stroke and Upper Extremity Hemiparesis, run by Christina Kruuse at 3 sites in Denmark.
Trial summary
In a double-blinded sham-controlled study the effect of patient-tailored transcranial direct current stimulation during rehabilitation training will be examined. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ischemic Stroke, Upper Extremity Hemiparesis
- What is being tested?
- Active Transcranial Direct Current Stimulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 22 participants
- Where
- 3 sitesDenmark
- Study dates
- 28 Aug 2022to Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Patients - Inclusion Criteria:
- Age >18 years
- Ischemic stroke confirmed by clinical and imaging criteria
- Hemiparesis including reduced upper-extremity function
- Location of stroke either cortically involving middle cerebral artery or the anterior cerebral artery circulation or subcortical (involving thalamus, basal ganglia).
- NIHSS score >2 and <8
- Modified Rankin Scale (mRS) ≤ 3
- Index of stroke within 4 weeks of inclusion
- Signed informed consent
Patients - Exclusion Criteria:
- >50% stenosis of extra- or intracranial artery as well as vascular malformations or aneurisms detected by brain CT-angiography.
- Exclusively ischemic stroke in spine, pons, brainstem, medulla or cerebellum.
- History of seizures, epilepsy, anxiety, dementia alcohol- or drug abuse.
- Prior serious head injury or neurosurgery
- Frequent severe headaches or migraine.
- Pregnancy or breastfeeding
- Current use of neuro-receptor/transmitter modulating medication, or medication interfering with seizure threshold (such as antiepileptic medication, some antidepressants, anxiety medication, antihistamines, stimulant drugs for attention deficit hyperactivity disorder).
- Pacemaker, implantable cardiac device unit (ICD-unit), metal fragments or other materials implanted not compatible with MRI (see appendix B).
- Claustrophobia
- Prior adverse effect to TDCS or Transcranial Magnetic Stimulation.
- Not able to provide informed consent.
- Terminally ill or short life expectancy.
Healthy controls - Inclusion criteria:
- Age between >18 years (matched to patients)
- Sex and age matched to patients
- Able bodied
- Have the ability to comply with all requirements of the study protocol, as determined by the investigator
- No history of stroke or dementia
- Eligible for MRI and TMS
Healthy controls - Exclusion Criteria:
- History of neurologic disease
- History of cerebral haemorrhage or brain damage
- Pregnancy
- Pacemaker or other implanted electronic devices
- Claustrophobia
- Psychiatric disorder
- Epilepsy or close relatives suffering from epilepsy
- Migraine
- Any contraindication to MRI or TMS
Trial locations and contacts
3 sites in 1 country.
Denmark3 sites, 3 recruiting
- Recruiting
Copenhagen University Department of Nutrition and Exercise
Copenhagen, 2200
Anke Karabanov, MSc, PhD, +4535328039, anke@nexs.ku.dk
Anke Karabanov, MSc, PhD
- Recruiting
Department of Neurology, Herlev Gentofte Hospital
Herlev, 2730
Christina Kruuse, MD, Prof, +4538681233
Mia Kolmos, MD, +4538681375, mia.kolmos@regionh.dk
- Recruiting
Danish Research Centre for Magnetic Resonance
Hvidovre, 2650
Hartwig R Siebner, MD, Prof, +4538626541, hartwig.roman.siebner@regionh.dk
Axel Thielscher, MSc, Prof, +4538623326, axelt@drcmr.dk
About this study
In a double-blinded sham-controlled study the effect of patient-tailored transcranial direct current stimulation during rehabilitation training will be examined.
Read the detailed description
Approximately two thirds of stroke patients have reduced motor function which have a large impact on both activities of daily living and quality of life. Only 12-34% achieve full motor recovery.
There is a growing interest in using non-invasive brain stimulation (NIBS) techniques to supplement neurorehabilitation. NIBS can modulate cortical excitability and is a powerful tool for motor rehabilitation post-stroke. Application Transcranial Direct Current Stimulation (TDCS) is currently emerging as a tool used in neurorehabilitaiton. Prior studies have shown that TDCS-stimulation prior to physical training may significantly improve of motor function post-stroke. However, up to 50% of the participants recieving active TDCS show no response to stimulation.
A one-size-fits-all approach to TDCS in stroke rehabilitation may not be optimal and a more precise and individualized targeting is warranted to stimulate functionally relevant areas.
In this study TDCS will be personalized for stroke patients with upper-extremity paresis using individual functional and structural Magnetic Resonance Imaging (MRI) and an electric field modelling pipeline developed at Danish Research Centre for Magnetic Resonance (DRMCR). Based on these measures the electric current induced by TDCS will individually target the area with residual neural activity during movement. The effect of personalized TDCS will be assessed by clinical measures of motor improvement. Sub-studies furthermore assess if the functional reorganization of motor networks is affected by personalized TDCS by application of functional magnetic resonance (fMRI) and.
The study will have 3 phases:
- Personalization: The stimulation profile of each patient will be individualized using structural MRI a pipeline for simulation based on MRI (SimNIBS) to make individual anatomical head models in order to estimate the best montage and current dosage. Further, task-based fMRI will be used to estimate residual motor activity location. The target current is set in the area displaying the highest residual motor activity in sensorimotor areas.
- Intervention: Four weeks upper extremity training program of specialized supervised physiotherapeutic training 3 times per week. Each training session consists of 2x 20 minutes of training with concurrent personalized TDCS stimulation or montage of equipment but no stimulation (sham). Each bloc of 20 minutes training is separated by a small break of 5-10 minutes. Both patient, therapist and investigator will be blinded to the stimulation mode (activ TDCS or sham)
- Follow-up: Immediately after the 4 weeks of intervention and 12 weeks after intervention has ended, follow-up with clinical examination and brain MRI will be done.
Ad baseline Transcranial Magnetic Stimulation (TMS) will be done as well to assess corticospinal integrity as well as estimation of intracortical inhibition.
Hypothesis:
The main hypothesis is that personalized ipsi-lesional anodal TDCS during specialized individualized arm-training will lead to significantly greater improvements in upper-extremity motor function compared to sham.
Substudy with healthy controls:
A cohort of 20 healthy age- and sex matched controls will be recruited for one session of MRI and TMS identical to the procedure of the patients at baseline as well as the same questionnaires (Protocol amendment approved by the local Ethics Committee the 10th October 2022).
These data will be analyzed in a substudy for normative comparison between the stroke patients and healthy age- and sex-matched controls.
Hypothesis - Healthy Controls:
Stroke patients will exhibit a higher laterality index measured by fMRI and a stronger degree of interhemispheric inhibition at baseline compared to healthy controls measued by task-related fMRI and by TMS iSP and SICI.
The degree of interhemispheric inhibition in stroke patients will normalize during recovery and be similar to normal controls at the last follow-up after 12 weeks.
Further, the degree of normalization of the interhemispheric inhibition in stroke patients will be proportional to degree of improvement of the upper-extremity measured by UE-FMA.
July 2024:
Due to challenging recruitment and at much lower recruitment rate than expected the trial design was changed from superiority to pilot- and feasibility trial. Therefore, the sample size was correspondingly adjusted to expected 24 with 12 participants in each of the two arms. Furthermore, outcome measures were re-prioritized to also contain feasibility outcome measures and primary outcome was changed to follow-up Fugl-Meyer Assessment score of upper-extremity (FMA-UE) adjusted for baseline in stead of change in FMA-UE from baseline to follow-up.
- Conditions
- Ischemic Stroke, Upper Extremity Hemiparesis
- Being tested
- Active Transcranial Direct Current Stimulation, Sham stimulation
- Keywords
- non-invasive brain stimulation, transcranial direct current stimulation, effective connectivity, functional connectivity, Fugl-Meyer Assessment, Functional Magnetic Resonance Imaging
- Medical subject headings
- Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Active Transcranial Direct Current StimulationDevice
See arm/group description
Sham stimulationDevice
See arm/group description
| Study group | Role | What they receive |
|---|---|---|
| Active Transcranial Direct Current Stimulation | Active comparator | Anodal TDCS 1mV for 2x 20 minutes. Receives: Device: Active Transcranial Direct Current Stimulation |
| Sham stimulation | Sham comparator | 2x 20 minutes of sham stimulation (30 sec ramp up, followed by current of 0 for 18.5 minutes followed by 30 sec ramp down). Receives: Device: Sham stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pilot outcome
Difference in Upper-extremity Fugl-Meyer Assessment (UE-FMA) score at end of treatment. Range 0-66.
Measured: From baseline to four months
Secondary outcomes (24)
Change in upper-extremity function
Difference in change in Action Reach Arm Test (ARAT) score. Range 0-57. High scores mean a better outcome.
Measured: From baseline to four months
Stroke severity
Difference in change in National Health Institutes Stroke Scale (NIHSS). Range 0-42. High scores mean a better outcome.
Measured: From baseline to four months
Stroke disability
Difference in change in Modified Rankin Scale (mRS). Range 0-6. Lower scores mean a better outcome.
Measured: From baseline to four months
ADL performance
Difference in change in Bartel's 20-item Index (BI-20). Range 0-100. Higher scores mean better outcome.
Measured: From baseline to four months
Gait speed
Difference in change in 10 Meter Walk Test (10MWT) in minutes:sec.
Measured: From baseline to four months
Physical Activity
Difference in change in Physical Activity Scale 2.0 (PAS2). The answers will be translated into a Metabolic Equivalent of Task (MET)-score. The higher MET-score the higher level of activity.
Measured: From baseline to four months
Montreal Cognitive Assessment
Difference in change in Montreal Cognitive Assessment (MoCA) score. Score range 0-30. Higher scores mean a better outcome.
Measured: From baseline to four months
Symbol Digit Modalities Test
Difference in change in Symbol Digit Modalities Test (SDMT) score. Score range 0-110. Higher scores mean a better outcome.
Measured: From baseline to four months
Health-related quality of life
Difference in change in EQ-5D-5L score. Range 1 to 20, a high score means low health-related quality of life. Includes a 0-100 visual analogue scale for overall percieved quality of life.
Measured: From baseline to four months
Becks Depression Inventory (BDI)
Difference in change in BDI-II score. Score range 0-63. Higher score means increased risk of depression.
Measured: From baseline to four months
Fatigue Severity Scale (FSS)
Difference in change in FSS score. Score range 0-7. Higher score means increased fatigue severity.
Measured: From baseline to four months
WHO-5 Well-Beeing Index
Difference in change in WHO-5 score. Score range 0-100. Higher score means better quality of life.
Measured: From baseline to four months
Biomarker of inflammation and exercise
Difference in change in serum level Cathepsin-B (unit mikro gram/L)
Measured: From baseline to four months
MRI - Cerebral bloodflow
Change in cerebral blood flow measured with arterial spin labeling (ASL) during rest
Measured: From baseline to four months
fMRI - Effective connectivity
Change in activation patterns measured with blood-oxygen-level dependent (BOLD) during both single and bimanual task.
Measured: From baseline to four months
fMRI - Interhemispheric inhibition
Change in activation pattern measured by blood-oxygen-level dependent (BOLD) during both single and bimanual task.
Measured: From baseline to four months
fMRI - Laterality Index
Change in activation pattern for hemispheric dominance measured by the ratio of active fMRI voxels in each hemisphere.
Measured: From baseline to four months
MRI - Corticospinal integrity
Change in corticospinal integrity measured by diffusion MRI.
Measured: From baseline to four months
MRI - Infarct lesion load
Difference in change in size of infarct lesion meaured by structural MRI.
Measured: From baseline to four months
Upper-extremity motor outcome
Follow-up Upper-extremity Fugl-Meyer Assessment (UE-FMA) score adjusted for baseline. Range 0-66
Measured: From baseline to four months
Feasibility: TDCS sensations
Proportion of participants experiencing sensations of TDCS (itching, pain, burning, vertigo, headache, fatigue, nausea, and/or other)
Measured: During intervention
Feasibility: Compliance to interventions
Proportion of TDCS-intervention sessions attended out of the 12 planned sessions
Measured: During intervention
Feasibilitiy: Compliance to home-exercises
Extent to which the participant has completed the planned home exercises ('fully', 'most', 'about 50%', 'below 50%', or 'not done')
Measured: During intervention
Feasibility: Patient feed-back
The patients are asked if they would recommend TDCS to a peer patient (Yes/No)
Measured: Follow-up1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 May 2022
- Study start28 Aug 2022
- Primary completionAug 2024 (estimated)
- Study completionDec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ischemic StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Intervention pilot- and feasibility trial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 22 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Christina Kruuse
- Sponsor type
- University, hospital or other
- Collaborators
- Danish Research Centre for Magnetic Resonance, The Novo Nordic Foundation, University of Copenhagen, Lundbeck Foundation
- Responsible party
- Sponsor-investigator, Christina Kruuse, Herlev Hospital
- Investigators
- Christina Kruuse, MD, Prof, Principal investigator, Herlev Gentofte Hospital, Department of Neurology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05355831
- Sponsor's protocol ID
- H-20036199
- Acronym
- PRACTISE
- Status last verified
- Jul 2024
- First submitted
- 26 Apr 2022
- Last updated
- 11 Jul 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD can be accessed upon reasonable request and after evaluation from the investigator.
Study at a glance
From the registry record, last updated by the sponsor on 11 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patient-tailored Transcranial Direct Current Stimulation to Improve Stroke Rehabilitation
- ClinicalTrials.gov ID
- NCT05355831
- Acronym / sponsor ID
- PRACTISE / H-20036199
- Conditions
- Ischemic Stroke, Upper Extremity Hemiparesis
- Keywords
- non-invasive brain stimulation, transcranial direct current stimulation, effective connectivity, functional connectivity, Fugl-Meyer Assessment, Functional Magnetic Resonance Imaging
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 22 participants (estimated)
- Lead sponsor
- Christina KruuseUniversity, hospital or other
- Collaborators
- Danish Research Centre for Magnetic Resonance, The Novo Nordic Foundation, University of Copenhagen, Lundbeck Foundation
- Study start
- 28 Aug 2022 (actual)
- Primary completion
- Aug 2024 (estimated)
- Study completion
- Dec 2024 (estimated)
- First posted
- 2 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In a double-blinded sham-controlled study the effect of patient-tailored transcranial direct current stimulation during rehabilitation training will be examined.
Detailed description
Approximately two thirds of stroke patients have reduced motor function which have a large impact on both activities of daily living and quality of life. Only 12-34% achieve full motor recovery.
There is a growing interest in using non-invasive brain stimulation (NIBS) techniques to supplement neurorehabilitation. NIBS can modulate cortical excitability and is a powerful tool for motor rehabilitation post-stroke. Application Transcranial Direct Current Stimulation (TDCS) is currently emerging as a tool used in neurorehabilitaiton. Prior studies have shown that TDCS-stimulation prior to physical training may significantly improve of motor function post-stroke. However, up to 50% of the participants recieving active TDCS show no response to stimulation.
A one-size-fits-all approach to TDCS in stroke rehabilitation may not be optimal and a more precise and individualized targeting is warranted to stimulate functionally relevant areas.
In this study TDCS will be personalized for stroke patients with upper-extremity paresis using individual functional and structural Magnetic Resonance Imaging (MRI) and an electric field modelling pipeline developed at Danish Research Centre for Magnetic Resonance (DRMCR). Based on these measures the electric current induced by TDCS will individually target the area with residual neural activity during movement. The effect of personalized TDCS will be assessed by clinical measures of motor improvement. Sub-studies furthermore assess if the functional reorganization of motor networks is affected by personalized TDCS by application of functional magnetic resonance (fMRI) and.
The study will have 3 phases:
- Personalization: The stimulation profile of each patient will be individualized using structural MRI a pipeline for simulation based on MRI (SimNIBS) to make individual anatomical head models in order to estimate the best montage and current dosage. Further, task-based fMRI will be used to estimate residual motor activity location. The target current is set in the area displaying the highest residual motor activity in sensorimotor areas.
- Intervention: Four weeks upper extremity training program of specialized supervised physiotherapeutic training 3 times per week. Each training session consists of 2x 20 minutes of training with concurrent personalized TDCS stimulation or montage of equipment but no stimulation (sham). Each bloc of 20 minutes training is separated by a small break of 5-10 minutes. Both patient, therapist and investigator will be blinded to the stimulation mode (activ TDCS or sham)
- Follow-up: Immediately after the 4 weeks of intervention and 12 weeks after intervention has ended, follow-up with clinical examination and brain MRI will be done.
Ad baseline Transcranial Magnetic Stimulation (TMS) will be done as well to assess corticospinal integrity as well as estimation of intracortical inhibition.
Hypothesis:
The main hypothesis is that personalized ipsi-lesional anodal TDCS during specialized individualized arm-training will lead to significantly greater improvements in upper-extremity motor function compared to sham.
Substudy with healthy controls:
A cohort of 20 healthy age- and sex matched controls will be recruited for one session of MRI and TMS identical to the procedure of the patients at baseline as well as the same questionnaires (Protocol amendment approved by the local Ethics Committee the 10th October 2022).
These data will be analyzed in a substudy for normative comparison between the stroke patients and healthy age- and sex-matched controls.
Hypothesis - Healthy Controls:
Stroke patients will exhibit a higher laterality index measured by fMRI and a stronger degree of interhemispheric inhibition at baseline compared to healthy controls measued by task-related fMRI and by TMS iSP and SICI.
The degree of interhemispheric inhibition in stroke patients will normalize during recovery and be similar to normal controls at the last follow-up after 12 weeks.
Further, the degree of normalization of the interhemispheric inhibition in stroke patients will be proportional to degree of improvement of the upper-extremity measured by UE-FMA.
July 2024:
Due to challenging recruitment and at much lower recruitment rate than expected the trial design was changed from superiority to pilot- and feasibility trial. Therefore, the sample size was correspondingly adjusted to expected 24 with 12 participants in each of the two arms. Furthermore, outcome measures were re-prioritized to also contain feasibility outcome measures and primary outcome was changed to follow-up Fugl-Meyer Assessment score of upper-extremity (FMA-UE) adjusted for baseline in stead of change in FMA-UE from baseline to follow-up.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Intervention pilot- and feasibility trial
| Arm | Type | Receives |
|---|---|---|
| Active Transcranial Direct Current Stimulation | Active comparator | Device: Active Transcranial Direct Current StimulationAnodal TDCS 1mV for 2x 20 minutes. |
| Sham stimulation | Sham comparator | Device: Sham stimulation2x 20 minutes of sham stimulation (30 sec ramp up, followed by current of 0 for 18.5 minutes followed by 30 sec ramp down). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active Transcranial Direct Current StimulationSee arm/group description | Device | Active Transcranial Direct Current Stimulation |
| Sham stimulationSee arm/group description | Device | Sham stimulation |
Primary outcome
Pilot outcome
Time frame: From baseline to four months
Difference in Upper-extremity Fugl-Meyer Assessment (UE-FMA) score at end of treatment. Range 0-66.
24 secondary outcomes
Change in upper-extremity function
Time frame: From baseline to four months
Stroke severity
Time frame: From baseline to four months
Stroke disability
Time frame: From baseline to four months
ADL performance
Time frame: From baseline to four months
Gait speed
Time frame: From baseline to four months
Physical Activity
Time frame: From baseline to four months
Montreal Cognitive Assessment
Time frame: From baseline to four months
Symbol Digit Modalities Test
Time frame: From baseline to four months
Health-related quality of life
Time frame: From baseline to four months
Becks Depression Inventory (BDI)
Time frame: From baseline to four months
Fatigue Severity Scale (FSS)
Time frame: From baseline to four months
WHO-5 Well-Beeing Index
Time frame: From baseline to four months
Biomarker of inflammation and exercise
Time frame: From baseline to four months
MRI - Cerebral bloodflow
Time frame: From baseline to four months
fMRI - Effective connectivity
Time frame: From baseline to four months
fMRI - Interhemispheric inhibition
Time frame: From baseline to four months
fMRI - Laterality Index
Time frame: From baseline to four months
MRI - Corticospinal integrity
Time frame: From baseline to four months
MRI - Infarct lesion load
Time frame: From baseline to four months
Upper-extremity motor outcome
Time frame: From baseline to four months
Feasibility: TDCS sensations
Time frame: During intervention
Feasibility: Compliance to interventions
Time frame: During intervention
Feasibilitiy: Compliance to home-exercises
Time frame: During intervention
Feasibility: Patient feed-back
Time frame: Follow-up1
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jul 2024.
- Individual participant dataSharing planned: Yes. IPD can be accessed upon reasonable request and after evaluation from the investigator.
Related trials for Ischemic Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Recruiting
Biomarkers of Paired VNS
Stroke, Ischemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christina Kruuse, MD, Prof principal investigator
Herlev Gentofte Hospital, Department of Neurology
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Active Transcranial Direct Current Stimulation in people with Ischemic Stroke and Upper Extremity Hemiparesis, run by Christina Kruuse at 3 sites in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 11 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Christina Krusse, MD, Prof (+4538681233, christina.kruuse@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pilot outcome (time frame: From baseline to four months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2024.